Blood cancer drug venetoclax could potentially be used to deplete HIV latently infected cells and delay viral rebound, leading to a potential cure for HIV, according to a study from researchers in Australia who tested the drug in humanized mice models.
Medimmune Ltd. has prepared and tested lipidated peptide analogues with improved stability acting as dual agonists of glucagon receptor (GCGR) and glucagon-like peptide 1 receptor (GLP-1R). They are reported to be useful for the treatment of obesity, nonalcoholic steatohepatitis (NASH) and type 2 diabetes.
Katholieke Universiteit Leuven and Springworks Therapeutics Inc. have jointly identified tetrahydropyridopyrimidines acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) or WW domain-containing transcription regulator protein 1 (WWTR1; TAZ)/TEAD interaction inhibitors.
A Retune Pharma Inc. patent describes new insulin-like growth factor 1 receptor (IGF-1R; CD221) inhibitors reported to be useful for the treatment of cancer, thyroid-associated ophthalmopathy (Graves ophthalmopathy) and autoimmune disease.
Serengen GmbH and Deargen Inc. have established a collaboration to accelerate the drug discovery process by bringing together Serengen’s novel DNA encoded library (DEL) technology with Deargen’s artificial intelligence (AI)-driven drug discovery platform, Deardti.
Researchers from Genentech Inc. presented preclinical data for the novel transient receptor potential ankyrin 1 (TRPA1) antagonist GDC-6599, currently in phase II development for respiratory indications.
The Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford have entered into a strategic partnership to accelerate the development of safe, effective and globally accessible vaccines against ‘disease X,’ the threat of unknown pathogens with the potential to cause pandemics.
Human lipoprotein(a) (Lp(a)) is a lipoprotein complex composed of a low-density lipoprotein (LDL) particle and a large highly polymorphic glycoprotein named apolipoprotein (a) (apo(a)). There is evidence that Lp(a) is linked to cardiovascular disorder risk.
RSS
